Divis Laboratories Stock Screener | Share Price & Fundamental Analysis
DIVISLAB
Pharmaceuticals
Share Price NSE
₹5850.00
▲
29.00 (0.50%)
Share Price BSE
₹5849.35
▲
39.10 (0.67%)
Track Divis Laboratories share price live with TickJournal's free stock screener.
Analyze Divis Laboratories share price history trends and compare 52-week high low
levels.
Record your trades in TickJournal's free trading journal and track your portfolio performance.
Divis Laboratories Market Cap
₹155,471.67 Cr.
DIVISLAB P/E Ratio (TTM)
63.26
Divis Laboratories P/B Ratio
10.17
EPS (TTM)
₹82.53
Dividend Yield
0.51%
Debt to Equity
-
DIVISLAB 52 Week High
₹6983.50
Divis Laboratories 52 Week Low
₹5386.15
Operating Margin
31.00%
Profit Margin
21.66%
DIVISLAB Revenue (TTM)
₹2,692.00
EBITDA
₹904.00
Net Income
₹583.00
Total Assets
₹16,932.00
Total Equity
₹14,969.00
Divis Laboratories Share Price History - Stock Screener Chart
Screen DIVISLAB historical share price movements with interactive charts. Analyze price trends and patterns.
Divis Laboratories Company Profile - Fundamental Screener
Screen Divis Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for DIVISLAB shares.
Divi's Laboratories Ltd is a leading pharmaceutical company specializing in the manufacture of Active Pharmaceutical Ingredients (APIs), Intermediates, and Nutraceuticals. The company operates globally with a presence in over 100 countries and has six manufacturing facilities. It offers both generic and custom synthesis services for pharmaceutical companies, supporting product development...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Ramesh B V Nimmagadda
ISIN
INE361B01024
Website
https://www.divislabs.com
Divis Laboratories Balance Sheet Screener
Screen DIVISLAB balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 16,932 | 15,470 | 14,439 | 13,375 | 10,774 | 8,536 | 8,038 | 6,786 | 6,159 | 4,902 |
| Current Assets | 10,081 | 9,675 | 9,312 | 8,352 | 6,175 | 4,680 | 4,650 | 4,535 | 4,011 | 3,027 |
| Fixed Assets | 5,442 | 4,739 | 4,723 | 4,325 | 3,704 | 2,782 | 2,088 | 1,996 | 1,559 | 1,439 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 511 | 621 | 571 | 451 | 367 | 299 | 234 | 208 | 142 | 89 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 14,969 | 13,571 | 12,767 | 11,728 | 9,295 | 7,310 | 6,957 | 5,925 | 5,357 | 4,293 |
| Share Capital | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 |
| Reserves & Surplus | 14,916 | 13,518 | 12,714 | 11,675 | 9,242 | 7,257 | 6,904 | 5,872 | 5,304 | 4,240 |
Divis Laboratories Income Statement Screener - Profit & Revenue Analysis
Screen Divis Laboratories income statement and profit fundamentals.
Analyze DIVISLAB quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Divis Laboratories share price evaluation.
| Item | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,692 | 2,860 | 2,529 | 2,671 | 2,401 | 2,444 | 2,197 | 2,382 | 1,950 | 1,995 | 1,859 | 2,017 | 1,821 | 1,935 | 2,343 |
| Expenses | 1,788 | 1,827 | 1,681 | 1,699 | 1,576 | 1,622 | 1,496 | 1,572 | 1,366 | 1,430 | 1,274 | 1,464 | 1,299 | 1,234 | 1,406 |
| EBITDA | 904 | 1,033 | 848 | 972 | 825 | 822 | 701 | 810 | 584 | 565 | 585 | 553 | 522 | 701 | 937 |
| Operating Profit % | 31.00% | 33.00% | 30.00% | 34.00% | 32.00% | 31.00% | 29.00% | 32.00% | 26.00% | 25.00% | 28.00% | 25.00% | 24.00% | 33.00% | 38.00% |
| Depreciation | 118 | 113 | 112 | 107 | 99 | 99 | 97 | 95 | 95 | 95 | 93 | 87 | 87 | 86 | 85 |
| Interest | 6 | 8 | 3 | 1 | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 780 | 912 | 733 | 864 | 726 | 722 | 604 | 713 | 489 | 469 | 492 | 466 | 435 | 615 | 852 |
| Tax | 197 | 223 | 188 | 202 | 137 | 212 | 174 | 175 | 131 | 121 | 136 | 145 | 129 | 122 | 150 |
| Net Profit | 583 | 689 | 545 | 662 | 589 | 510 | 430 | 538 | 358 | 348 | 356 | 321 | 306 | 493 | 702 |
| EPS | 21.98 | 25.97 | 20.49 | 24.93 | 22.20 | 19.20 | 16.20 | 20.25 | 13.50 | 13.11 | 13.41 | 12.09 | 11.56 | 18.60 | 26.44 |
Divis Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen DIVISLAB cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 1,653 | 1,261 | 2,460 | 1,912 | 1,947 | 1,216 | 954 | 776 | 1,150 | 1,038 |
| Investing Activities | -804 | -269 | -2,708 | -2,195 | 75 | -84 | -685 | -478 | -1,140 | -406 |
| Financing Activities | -799 | -799 | -797 | -532 | -35 | -1,091 | -246 | -314 | 2 | -631 |
| Net Cash Flow | 50 | 193 | -1,045 | -816 | 1,987 | 41 | 23 | -17 | 13 | 0 |
Divis Laboratories Shareholding Pattern Screener
See Divis Laboratories shareholding pattern with promoter, FII, and DII holdings.
Check Divis Laboratories promoter holding and ownership changes for DIVISLAB on TickJournal.
| Item | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 51.88% | 51.89% | 51.89% | 51.89% | 51.89% | 51.89% | 51.90% | 51.92% |
| FII Holding | 20.08% | 19.39% | 19.74% | 18.01% | 17.99% | 17.25% | 16.16% | 14.68% |
| DII Holding | 19.28% | 19.76% | 19.05% | 20.71% | 20.54% | 21.06% | 21.77% | 22.21% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 6.61% | 6.78% | 7.05% | 7.17% | 7.32% | 7.41% | 7.77% | 8.69% |
| Other Holding | 2.15% | 2.18% | 2.27% | 2.22% | 2.26% | 2.39% | 2.41% | 2.50% |
| Shareholder Count | 233,844 | 249,634 | 259,825 | 267,755 | 280,601 | 278,899 | 298,310 | 347,629 |
Divis Laboratories Share Dividend Screener - Share Yield Analysis
Check Divis Laboratories dividend history with payout and yield data.
View Divis Laboratories dividend details including ex-dates and amounts for DIVISLAB stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹30.00 | 0.50% |
| 2024-March | ₹30.00 | 0.52% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹30.00 | 1.06% |
| 2021-March | ₹20.00 | 0.45% |
| 2020-March | ₹16.00 | 0.44% |
| 2019-March | ₹16.00 | 0.80% |
| 2018-March | ₹10.00 | 0.59% |
| 2017-March | ₹10.00 | 0.92% |
Divis Laboratories Stock Index Membership
See which indices include Divis Laboratories stock.
Check DIVISLAB index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE 200 EQUAL WEIGHT
BSE INDEX BSE HC
BSE INDEX BSE100
BSE INDEX BSE200
BSE INDEX BSE500
BSE INDEX BSEDSI
BSE INDEX BSEMOI
BSE INDEX DOL100
BSE INDEX LCTMCI
BSE INDEX LMI250
BSE INDEX LRGCAP
BSE INDEX MFG
BSE INDEX SNXT50
NIFTY 100
NIFTY 200
NIFTY 500
NIFTY ALPHA 50
NIFTY ALPHA QUALITY LOW-VOLATILITY 30
NIFTY ALPHALOWVOL
NIFTY GROWSECT 15
NIFTY HEALTHCARE
NIFTY INDIA MFG
NIFTY LARGEMID250
NIFTY LOW VOLATILITY 50
NIFTY NEXT 50
NIFTY PHARMA
NIFTY TOTAL MKT
NIFTY100 ALPHA 30
NIFTY100 ENHANCED ESG
NIFTY100 EQL WGT
NIFTY100 ESG
NIFTY100 QUALTY30
NIFTY200 ALPHA 30
NIFTY200MOMENTM30
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MOMENTUM 50
NIFTY500 MULTICAP
Divis Laboratories Market Events Screener - Corporate Actions
Get Divis Laboratories corporate actions including splits, bonuses, and buybacks.
Check Divis Laboratories stock events that may affect DIVISLAB share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-02-11 | 2026-02-11 | Quarterly Result Announcement | NA | 2.27% |
| 2025-11-07 | 2025-11-07 | Quarterly Result Announcement | NA | 4.41% |
| 2025-08-11 | 2025-08-11 | Annual General Meeting | NA | -5.90% |
| 2025-08-06 | 2025-08-06 | Quarterly Result Announcement | NA | -3.17% |
| 2025-07-25 | 2025-07-25 | Dividend | ₹ 30.00 /share | 5.37% |
| 2025-05-17 | 2025-05-17 | Quarterly Result Announcement | NA | 2.17% |
| 2025-02-03 | 2025-02-03 | Quarterly Result Announcement | NA | -3.47% |
| 2024-11-09 | 2024-11-09 | Quarterly Result Announcement | NA | 2.13% |
| 2024-08-12 | 2024-08-12 | Annual General Meeting | NA | 17.15% |
| 2024-08-02 | 2024-08-02 | Dividend | ₹ 30.00 /share | 19.29% |
| 2023-08-11 | 2023-08-11 | Dividend | ₹ 30.00 /share | 20.91% |
| 2022-08-11 | 2022-08-12 | Dividend | ₹ 30.00 /share | -8.33% |
| 2021-08-17 | 2021-08-20 | Dividend | ₹ 20.00 /share | 19.22% |
Divis Laboratories Competitors Screener - Peer Comparison
Screen DIVISLAB competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 406,351 | 37.86 | 54,729 | 9.71% | 10,980 | 37.98 |
| Divis Laboratories | 155,472 | 63.26 | 9,712 | 18.67% | 2,191 | 33.24 |
| Torrent Pharmaceuticals | 134,945 | 61.20 | 11,539 | 6.99% | 1,911 | 32.75 |
| Lupin | 103,954 | 22.26 | 22,910 | 13.74% | 3,306 | 47.35 |
| Dr Reddys Laboratories | 101,601 | 18.27 | 33,741 | 16.73% | 5,725 | 39.36 |
| Cipla | 96,320 | 21.31 | 28,410 | 7.12% | 5,291 | 26.86 |
| Zydus Life Science | 86,964 | 17.29 | 23,511 | 18.55% | 4,615 | 41.42 |
| Mankind Pharma | 82,499 | 45.81 | 12,744 | 20.90% | 2,007 | 41.40 |
| Aurobindo Pharma | 77,462 | 22.37 | 32,346 | 9.43% | 3,484 | 64.38 |
| Alkem Laboratories | 62,867 | 25.87 | 13,458 | 3.70% | 2,216 | 42.54 |
Divis Laboratories Company Announcements - News Screener
Screen DIVISLAB latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-04-04 | Closure of Trading Window | - |
| 2026-03-21 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-03-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-14 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-02-12 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-11 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-02-11 | Board Meeting Outcome for Outcome Of Board Meeting Held On February 11 2026 | - |
| 2026-02-03 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-01-30 | Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2025. | - |
| 2026-01-03 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2025-12-31 | Closure of Trading Window | - |
| 2025-11-14 | Regulation 30 Disclosure - US-FDA Inspection Of CompanyS Unit-I Manufacturing Facility At Lingojigudem Village Yadadri Bhuvanagiri District Telangana India | - |
| 2025-11-12 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2025-11-08 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2025-11-07 | Board Meeting Outcome for Outcome Of Board Meeting | - |
| 2025-10-29 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2025-10-27 | Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025. | - |